These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 3592889)

  • 21. [Use of bromocriptine in Parkinson diseases in low doses at a slow rate. 40 patients].
    Liaño H; López-Lozano JJ; Ramírez A; Rabes C; Pascual ML
    Arch Neurobiol (Madr); 1984; 47(3):143-50. PubMed ID: 6508478
    [No Abstract]   [Full Text] [Related]  

  • 22. [Acute study of the association of bromocriptine and domperidone in parkinsonism (author's transl)].
    Pollak P; Gaio JM; Hommel M; Pellat J; Chateau R
    Therapie; 1981; 36(6):671-6. PubMed ID: 7342355
    [No Abstract]   [Full Text] [Related]  

  • 23. "Long term evaluation of combined treatment of Parkinson disease with L-dopa, peripheral decarboxylase inhibitors and bromocreptine".
    Caraceni T; Giovannini P; Girotti F; Parati E; Pederzoli M; Scigliano G
    Ital J Neurol Sci; 1981 Dec; 2(4):337-42. PubMed ID: 7333824
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lisuride treatment in Parkinson's disease: clinical and pharmacokinetic studies.
    LeWitt PA; Burns RS; Calne DB
    Adv Neurol; 1983; 37():131-40. PubMed ID: 6344586
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Oral lisuride in Parkinson's disease].
    Obeso JA; Luquin MR; Martínez Lage JM
    Med Clin (Barc); 1985 Sep; 85(8):307-12. PubMed ID: 4068822
    [No Abstract]   [Full Text] [Related]  

  • 26. [Secondary effects of prolonged levodopa therapy in Parkinson's disease].
    Peiró Grasa A; Grau-Veciana JM
    Med Clin (Barc); 1985 Jun; 85(3):88-91. PubMed ID: 4021630
    [No Abstract]   [Full Text] [Related]  

  • 27. Pergolide in late-stage Parkinson disease.
    Lang AE; Quinn N; Brincat S; Marsden CD; Parkes JD
    Ann Neurol; 1982 Sep; 12(3):243-7. PubMed ID: 6753730
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Conversion from dopamine agonists to pramipexole. An open-label trial in 227 patients with advanced Parkinson's disease.
    Linazasoro G;
    J Neurol; 2004 Mar; 251(3):335-9. PubMed ID: 15015015
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Parlodel: a new therapeutic possibility in the management of Parkinson disease].
    Glaub T; Berecz G; Pintér N; Diószeghy P; Virga A; Mechler F
    Orv Hetil; 1988 Feb; 129(8):399-402. PubMed ID: 3279375
    [No Abstract]   [Full Text] [Related]  

  • 30. The Parkinson-Control study: a 1-year randomized, double-blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson's disease.
    Castro-Caldas A; Delwaide P; Jost W; Merello M; Williams A; Lamberti P; Aguilar M; Del Signore S; Cesaro P;
    Mov Disord; 2006 Apr; 21(4):500-9. PubMed ID: 16267842
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A comparative study of bromocriptine and levodopa in Parkinson's disease.
    Duvoisin RC; Mendoza MM; Yahr MD
    Adv Biochem Psychopharmacol; 1980; 23():271-5. PubMed ID: 7395618
    [No Abstract]   [Full Text] [Related]  

  • 32. Kinetic-dynamic monitoring of levetiracetam effects in patients with Parkinson disease and levodopa-induced dyskinesias.
    Contin M; Martinelli P; Albani F; Scaglione C; Avoni P; Rizzo G; Baruzzi A
    Clin Neuropharmacol; 2007; 30(2):122-4. PubMed ID: 17414945
    [No Abstract]   [Full Text] [Related]  

  • 33. Psychiatric effects of bromocriptine and lergotrile in Parkinsonian patients.
    Serby M; Angrist B; Lieberman A
    Adv Biochem Psychopharmacol; 1980; 23():287-92. PubMed ID: 6104908
    [No Abstract]   [Full Text] [Related]  

  • 34. [Neurologic indications for bromocriptine (in addition to Parkinson's disease)].
    Destee A
    LARC Med; 1984 Feb; 4(2):107-11. PubMed ID: 6232436
    [No Abstract]   [Full Text] [Related]  

  • 35. [Bromocriptine in Parkinson's disease. Personal experience].
    Chacón JR; Piqueras L; Pery JM
    Arch Neurobiol (Madr); 1982; 45(5):371-80. PubMed ID: 7165448
    [No Abstract]   [Full Text] [Related]  

  • 36. [Treatment of Parkinson disease by bromocriptine in the black African].
    Ndiaye IP; Jacquin-Cotton L; Martini L
    Dakar Med; 1980; 25(2):131-5. PubMed ID: 7215100
    [No Abstract]   [Full Text] [Related]  

  • 37. Therapeutic results with a new ergoline derivate (8-alpha-amino-ergoline, CU 32-085) in parkinsonian patients.
    Schneider E; Hubener K; Fischer PA
    Adv Neurol; 1984; 40():527-9. PubMed ID: 6695631
    [No Abstract]   [Full Text] [Related]  

  • 38. [Bromocriptine in the treatment of patients with parkinsonism and dyskinesias induced by levodopa].
    Haas JA; Lakke JP
    Ned Tijdschr Geneeskd; 1982 Apr; 126(16):701-5. PubMed ID: 7088202
    [No Abstract]   [Full Text] [Related]  

  • 39. [Bromocriptine in the treatment of Parkinson's disease].
    Sepcić J; Ledić P
    Neurologija; 1982; 30(1-4):75-81. PubMed ID: 6765062
    [No Abstract]   [Full Text] [Related]  

  • 40. The response of "de novo" Parkinson's disease patients to bromocriptine in a "low and slow" regimen is predictive for prognosis.
    Sampaio C; Coelho T; Castro-Caldas A; Bastos-Lima A; Levy A
    J Neural Transm Suppl; 1995; 45():197-202. PubMed ID: 8748626
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.